Corixa

Company type	biotechnology/pharmaceutical
Founded	1994 in Seattle, Washington
Defunct	March 31, 2006 (2006-03-31)
Successor	acquired by GlaxoSmithKline
Headquarters	Seattle , Washington
Number of locations	2
Parent	GlaxoSmithKline (United States)

Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.

The name Corixa comes from the true bug (Insecta: Hemiptera: Heteroptera) genus Corixa (family Corixidae, Water boatman), described by Geoffroy, in 1762.^{[citation needed]}

On 12 July 2005^{[citation needed]}, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.^[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.

On 31 March 2006, Corixa's doors closed after over 11 years in business.^{[citation needed]}